Xxxxxxx Additional Development Sample Clauses

Xxxxxxx Additional Development. In the event Geron exercises its US Opt-In Rights under Section 2.2.2 and in the case that Xxxxxxx is the Proposing Party under Section 4.9.3 and successfully conducts a Proposed Trial ( which, for clarity, would not include any Ex-US Study) under a Xxxxxxx IDP at its expense and obtains Regulatory Approval based on data from such trial (such as to expand any Licensed Product labeling to include a new Oncology Indication supported by the trial) (such Regulatory Approval, a “Xxxxxxx IDP Based Regulatory Approval”), it shall so notify Geron in writing of such Xxxxxxx IDP Based Regulatory Approval, and provide a reasonably detailed accounting of Xxxxxxx’x Out-of-Pocket Costs and FTE Costs reasonably incurred in conducting such Proposed Trial (for clarity, other than an Ex-US Study) under Xxxxxxx’x IDP (the “Xxxxxxx IDP Trial Costs”), in which event Geron shall pay Xxxxxxx an amount equal to [*] percent ([*]%) of the Xxxxxxx IDP Trial Costs (the “Geron Reimbursement [*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Amount”), which Geron Reimbursement Amount will be due upon Xxxxxxx’x receipt of the Xxxxxxx IDP Based Regulatory Approval and payable as follows: at Geron’s election by notice to Xxxxxxx provided within [*] ([*]) days of Geron’s receipt of the notice of the Xxxxxxx IDP Based Regulatory Approval for a particular Additional Study under a Xxxxxxx IDP, Geron shall pay, within [*] ([*]) days of such notice and Xxxxxxx’x provision of an invoice, an amount (the “Geron Reimbursement Downpayment”) that is the lesser of: (i) the full Geron Reimbursement Amount; or (ii) an amount equal to the greater of [*] US dollars ($[*]) and [*] percent ([*]%) of the total amounts paid by Xxxxxxx to Xxxxx in the prior [*] ([*]) months in the form of upfront or milestone payments or royalties. With such payment of the Geron Reimbursement Downpayment, Geron shall and hereby does xxxxx Xxxxxxx a credit and right of offset for [*] as assessed pursuant to Section 9.9 (the [“*”]), which credit Xxxxxxx may thereafter apply in accordance with Section 9.8.1, for any [*]. Notwithstanding anything to the contrary herein, Geron’s right under this Section 4.9.5 to [*] shall be subject to Section 9.8, including the Balance Ceiling under Section 9.8.2.
AutoNDA by SimpleDocs

Related to Xxxxxxx Additional Development

  • Clinical Development (a) Stellartech shall design, develop and construct a Clinical Unit for each of the Thermage Disposable Device and the Thermage Generator, and any required component or subassembly thereof and shall deliver such Clinical Units to Thermage in accordance with the Development Program; (b) Stellartech shall deliver to Thermage such other Deliverables as are contemplated by the Development Program in accordance with the Development Program; and (c) as requested by Thermage and automatically at the conclusion of the Development Program, Stellartech, so long as Thermage is not in breach of its material obligation hereunder, shall deliver in writing to Thermage any and all data and information held by or in the control of Stellartech which is necessary or useful to obtain regulatory approval of the Products in the United States or any foreign country.

  • Initial Development Plan Not later than the Effective Date, Licensee shall have provided Merck with an initial Development plan for the Licensed Product in the Field in the Territory, which shall be incorporated as part of this Agreement as Attachment 3.02(a) (as may be amended in accordance with this Agreement, the “Development Plan”). **CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  • Information Systems Acquisition Development and Maintenance a. Client Data – Client Data will only be used by State Street for the purposes specified in this Agreement.

  • Joint Development All inventions, know-how, trade secrets, data or information which result from joint development by the Parties hereto shall be jointly owned by the Parties. The Parties hereby agree to cooperate in good faith in the filing of any and all patent applications in all jurisdictions.

  • Business Development Company Buyer is a business development company as defined in Section 202(a)(22) of the Investment Advisors Act of 1940.

  • Business Development Provide advice and assistance in business growth and development of Party B. 业务发展。对乙方的业务发展提供建议和协助。

  • Research and Development (i) Advice and assistance in relation to research and development of Party B;

  • Notice of Material Developments Each Party shall give prompt written notice to the other Parties of: (a) any material variances in any of its representations or warranties contained in Articles 2 or 3 above, as the case may be (the Disclosure Schedule); (b) any breach of any covenant or agreement hereunder by such Party; and (c) any other material development which adversely affects the ability of such Party to consummate the transactions contemplated by this Agreement.

  • Business Development Company Status The Company, during a period of at least 12 months from the Closing Time, will use its commercially reasonable efforts to maintain its status as a business development company; provided, however, the Company may cease to be, or withdraw its election as, a business development company, with the approval of the board of directors and a vote of stockholders as required by Section 58 of the 1940 Act or any successor provision.

  • Status as Business Development Company The Borrower is an “investment company” that has elected to be regulated as a “business development company” within the meaning of the Investment Company Act and qualifies as a RIC.

Time is Money Join Law Insider Premium to draft better contracts faster.